AbbVie Inc. · Q4 2023
ReportedFeb 2, 2024
Period endedDec 31, 2023
Rule of 40+26
The quarter in short
Revenue $14.30B, down 5.4% year over year and up 2.7% on the quarter. EPS $0.45, down 67.9% year over year and 55.0% on the quarter. Free cash flow $4.55B, down 37.0% year over year and 38.2% on the quarter. Rule of 40 score +26.
Reported this quarter
Revenue
$14.30B
QoQ +2.7%
YoY −5.4%
EPS
$0.45
QoQ −55.0%
YoY −67.9%
Free Cash Flow
$4.55B
QoQ −38.2%
YoY −37.0%
Gross Margin
70.8%
QoQ +2.1 pp
YoY −1.7 pp
FCF Margin
31.8%
QoQ −21.0 pp
YoY −15.9 pp
P/E Ratio
52.5
QoQ +40.4%
YoY +141.6%
Each tile opens the full quarterly series. Download the numbers as CSV or JSON.
Sources & downloads
Company
Published by the company on the day of the release.
HTML
Earnings press release
Investor relations announcement
SEC filings
Filed with the SEC under CIK 1551152.
HTML
8-K results announcement
Filed Feb 2, 2024
HTM
Press release (EX-99.1)
Exhibit 99.1 to the 8-K
487 KB
HTML
Filing index
Every document in the 8-K submission
TXT
Complete submission
Raw archival text of the whole filing
HTML
10-K annual report
Period ended Dec 31, 2023, filed Feb 20, 2024
ZIP
XBRL data bundle
Structured financial statements from the 10-K
JSON
Company facts (XBRL)
Every figure ABBV has reported to the SEC
R40 data
The numbers shown on this page, as we hold them.
CSV
This quarter (CSV)
Reported metrics for Q4 2023, spreadsheet-ready
JSON
This quarter (JSON)
Metrics, dates and matched filings